ABSTRACT
Thrombo-embolic complications after Corona virus disease-19 (COVID-19) vaccination have been previously reported. We aimed to study the coronary thrombo-embolic complications (CTE) after COVID-19 vaccination in a single centre during the initial 3 months of vaccination drive in India. All patients admitted to our hospital between 1st March 2021 and 31st May 2021 with Acute coronary syndrome (ACS) were included. Of the 89 patients [Age 55 (47e64)y, 13f] with ACS and angiographic evidence of coronary thrombus, 37 (42%) had prior vaccination history. The timing from last vaccination dose to index event was <1, 1e2, 2e4 and >4 weeks in 9(24%), 4(11%), 15(41%) and 9 (24%) respectively. ChAdOx1 nCoV-19/AZD1222 (Covishield) was the most used vaccine- 28 (76%), while 9 (24%) had BBV152 (Covaxin). Baseline characteristics were similar in both vaccinated (VG) and non-vaccinated group (NVG), except for symptom to door time [8.5 (5.75e14) vs 14.5 (7.25e24) hrs, p ¼ 0.003]. Thrombocytopenia was not noted in any of the VG patients, while 2 (3.8%) of NVG patient had thrombocytopenia (p ¼ 0.51). The pre- Percutaneous Coronary Intervention (PCI) Thrombolysis in Myocardial Infarction (TIMI) flow was significantly lower [1 (0e3) vs2 (1e3), p ¼ 0.03) and thrombus grade were significantly higher [4 (2.5e5) vs 2 (1e3), p ¼ 0.0005] in VG. The in-hospital (2.7% vs 1.9%, p ¼ 1.0) and 30-day mortality were also similar (5.4% vs 5.8%, p ¼ 1.0). This is the first report of CTE after COVID-19 vaccination during the first 3 months of vaccination drive in India. We need further reports to identify the incidence of this rare but serious adverse events following COVID-19 vaccination.
ABSTRACT
The present study was conducted at Panna Tiger Reserve of Madhya Pradesh for sero-surveillance for canine parvovirus (CPV), canine distemper virus (CDV) and canine adenovirus (CAV) infections in feral dogs. Biological samples were also collected from the wild carnivore species which were immobilized or died during the study period. Serum samples were subjected for detection of IgG antibodies against CPV, CDV and CAV infections. Additionally biological samples of wild carnivores were subjected to molecular diagnosis of CPV and CDV genes. Seroprevalence for CPV, CDV and CAV infections was observed as 3.5%, 4.4% and 0.89%, respectively, whereas for mixed infections of CPV+CDV, CPV+CAV, CDV+CAV and CPV+CDV+CAV, it was observed as 48.2%, 1.7%, 4.4% and 36.6%, respectively. Sex wise, age wise and distance wise seroprevalence was non-significant in the present study. Seroprevalence for CPV, CDV and CAV infections in cats was observed as 50%, 100 % and 0%, whereas in wild carnivores, it was observed as 100%, 90% and 0% respectively. PCR based diagnosis in the wild carnivore also revealed CDV positive cases. Serological and genomic evidence of pathogens in dogs-cats of buffer villages and wild carnivores of Panna tiger reserve indicated that the viruses may pose a high risk of spillover to wild carnivores. Study also indicated that dog population is immuned to major infectious diseases but can be a threat to the compromised wild carnivore species including tigers